Citi lowered the firm’s price target on Bruker (BRKR) to $75 from $80 and keeps a Buy rating on the shares post the Q3 report. Bruker saw ongoing softness in China and in biopharma in the quarter, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target lowered to $75 from $78 at Wells Fargo
- Bruker price target lowered to $69 from $75 at Barclays
- Bruker Corporation Reports Strong Revenue Growth in Q3 2024
- Bruker price target lowered to $78 from $79 at BofA
- Morning Movers: GlobalFoundries and Apollo Global gain following Q3 results